Free Deal Calculator

Calculate RNAi Deal Values in Minutes

Get precise licensing valuations with real market data from $700M-$2.5B deals

Real-Time Market Data

Access current RNAi and siRNA deal benchmarks with 15% market premium calculations. Our database tracks Phase 2 upfronts from $60M-$250M across all major therapeutic areas.

Instant Valuation Results

Generate comprehensive deal structures in under 5 minutes. Compare milestone payments, royalty rates, and total deal values against recent market transactions.

Industry-Validated Models

Built with input from BD executives and validated against actual closed deals. Our algorithms account for target specificity, delivery mechanisms, and competitive landscapes.

$2.5B

Max Deal Values Tracked

150+

RNAi Deals Analyzed

94%

Valuation Accuracy Rate

15%

Current Market Premium

How It Works

Input Your Asset Details

Enter development stage, therapeutic area, target profile, and competitive positioning for your RNAi or siRNA program.

Apply Market Conditions

Select current market dynamics and specify deal preferences including geography, partner type, and strategic priorities.

Generate Deal Structure

Receive detailed valuation report with upfront payments, milestone schedules, royalty tiers, and comparable transaction analysis.

Frequently Asked Questions

How does the 15% market premium affect RNAi deal valuations?

The current 15% premium reflects strong investor confidence in RNAi therapeutics following recent clinical successes. This premium is applied to baseline valuations across all deal components including upfronts, milestones, and royalty rates.

What factors drive the wide range in Phase 2 upfront payments?

Phase 2 upfronts ($60M-$250M) vary based on target validation, delivery technology maturity, competitive landscape, and partner strategic fit. Programs with validated targets and proven delivery systems command premium upfronts.

How accurate are the total deal value projections?

Our models achieve 94% accuracy by analyzing actual deal structures, not just headline numbers. We factor in probability-adjusted milestones and realistic commercial projections based on comparable launches.

Does the calculator account for different RNAi delivery platforms?

Yes, our models differentiate between delivery approaches including LNPs, GalNAc conjugates, and emerging platforms. Each delivery method has distinct risk profiles and valuation multiples in our database.

Ready to Calculate Your Deal Terms?

Get instant benchmarks based on real market data from recent biotech licensing deals.

Start Calculating